Italia markets open in 18 minutes

DaVita Inc. (0I7E.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
92,36-1,38 (-1,47%)
Alla chiusura: 06:04PM BST
Schermo intero
Chiusura precedente93,74
Aperto94,75
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno92,36 - 94,75
Intervallo di 52 settimane92,36 - 94,75
Volume0
Media VolumeN/D
Capitalizzazione15,517B
Beta (5 anni mensile)1,13
Rapporto PE (ttm)10,91
EPS (ttm)8,46
Prossima data utili01 ago 2022 - 05 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Miromatrix to Ring Nasdaq Closing Bell on National Donor Day, February 14, 2022

    EDEN PRAIRIE, Minn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that the Company will ring the closing bell at Nasdaq on Monday, February 14, 2022, at 4:00 p.m. ET to celebrate National Donor Day and the Company’s public listing last year on Nasdaq under the trading symbol MIRO. Miromatrix CEO, Jeff Ross, Ph.D., wi

  • GlobeNewswire

    Renalytix Reports Full Year Fiscal 2021 Results

    LONDON and SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces its results for the twelve months ended 30 June 2021. Highlights: Regulatory & Reimbursement Government-wide contract granted by the U.S. General Services Administration for KidneyIntelX™ testing s

  • GlobeNewswire

    Miromatrix Welcomes Dr. John Barry as Vice President of Research and Development

    EDEN PRAIRIE, Minn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced the hiring of Dr. John Barry as Vice President of Research and Development. Dr. Barry will be leading the activities for the development of the Company's transplantable liver and kidney programs including the use of a bio-engineered liver in an